Disease relevance of Bilopaque

• Tyropanoate cholecystography and reversible renal failure [1].
• Recently, successful oral cholecystography has been described during the acute episode of pancreatitis, using Bilopaque, a more water-soluble cholecystopaque [2].
• Prolonged treatment of hyperthyroidism with sodium tyropanoate, an oral cholecystographic agent: a re-evaluation of its clinical utility [3].
• Oral cholecystography in the early phase of acute alcoholic pancreatitis. A prospective, randomized comparison of Telepaque and Bilopaque [2].

High impact information on Bilopaque

• The order of potency was BSP greater than ipodate greater than iopanoate greater than tyropanoate [4].
• For maximum, first-dose gallbladder opacification during clinical cholecystography, iopanoic acid should be given with a meal and sodium ipodate while the patient is fasting; diet makes no difference with sodium tyropanoate [5].
• To determine the influence of diet and fasting on gallbladder opacification during oral cholecystography, 10 dogs were studied in a blind, random fashion, giving single or two consecutive doses of iopanoic acid, sodium tyropanoate, or sodium ipodate while the animals were fasting, on a normal diet, or on a low-fat diet [5].
• Bile, plasma, urine, and hepatic tissue were analyzed by high-pressure liquid chromatography for the presence of tyropanoate, enantiomers of tyropanoate glucuronide, and other typropanoate metabolites [6].

Analytical, diagnostic and therapeutic context of Bilopaque

• Consequently, 1) tyropanoate OCG adequately opacifies the gallbladder in most patients with acute pancreatitis who are fasting or taking liquids only; 2) allows gallbladder evaluation earlier than with iopanoic acid OCG; 3) is less affected by hepatic dysfunction; and 4) provides an alternative to ultrasonography [7].

References